- Home
- REAL vs ZURA Comparison
REAL vs ZURA Comparison
Compare REAL & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- ZURA
- Stock Information
- Founded
- REAL 2011
- ZURA 2022
- Country
- REAL United States
- ZURA United States
- Employees
- REAL N/A
- ZURA N/A
- Industry
- REAL Other Specialty Stores
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REAL Consumer Discretionary
- ZURA Health Care
- Exchange
- REAL Nasdaq
- ZURA Nasdaq
- Market Cap
- REAL 1.4B
- ZURA 137.2M
- IPO Year
- REAL 2019
- ZURA N/A
- Fundamental
- Price
- REAL $11.52
- ZURA $3.45
- Analyst Decision
- REAL Strong Buy
- ZURA Buy
- Analyst Count
- REAL 5
- ZURA 9
- Target Price
- REAL $12.20
- ZURA $11.00
- AVG Volume (30 Days)
- REAL 3.1M
- ZURA 790.7K
- Earning Date
- REAL 11-10-2025
- ZURA 11-07-2025
- Dividend Yield
- REAL N/A
- ZURA N/A
- EPS Growth
- REAL N/A
- ZURA N/A
- EPS
- REAL N/A
- ZURA N/A
- Revenue
- REAL $636,971,000.00
- ZURA N/A
- Revenue This Year
- REAL $14.56
- ZURA N/A
- Revenue Next Year
- REAL $10.14
- ZURA N/A
- P/E Ratio
- REAL N/A
- ZURA N/A
- Revenue Growth
- REAL 12.68
- ZURA N/A
- 52 Week Low
- REAL $2.93
- ZURA $0.97
- 52 Week High
- REAL $12.84
- ZURA $4.85
- Technical
- Relative Strength Index (RSI)
- REAL 49.81
- ZURA 52.02
- Support Level
- REAL $11.89
- ZURA $3.72
- Resistance Level
- REAL $12.50
- ZURA $3.91
- Average True Range (ATR)
- REAL 0.64
- ZURA 0.25
- MACD
- REAL -0.08
- ZURA -0.06
- Stochastic Oscillator
- REAL 40.32
- ZURA 30.93
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.